Philosophy of Care
Dr. Valicenti believes in being tough on cancer, using a multi-disciplinary team approach and leading therapeutic weapons to maximize outcomes while preventing side effects. He emphasizes that innovation is critical to the advancement of new cancer treatments and that education is essential for the benefit of patients, families and the next-generation of cancer caregivers. Dr. Valicenti is nationally and internationally recognized in the treatment of prostate cancer and other tumors.
Dr. Valicenti's clinical interests focus on prostate cancer, gynecologic tumors, genitourinary malignancies and brain tumors. He is also interested in the use of prostate seed implantation and Gamma Knife for cancer treatment.
Dr. Valicenti is conducting clinical research to evaluate multi-modality therapies for clinically localized prostate cancer. In addition, he is carrying out outcome-based studies addressing quality-of-life questions and exploratory analyses of large databases.
4501 X St.
Sacramento, CA 95817
M.A., Columbia University Graduate School, New York, New York, 1984
B.S., Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts, 1981
American Society of Therapeutic Radiology and Oncology
Select Honors and Awards:
Best Doctors in America, Radiation Oncology, 2005-2013,
Resident Travel Award, American Society of Therapeutic Radiology and Oncology (Faculty Advisor), 2006,
Sigma Xi Award for Medical Student Research (Faculty Advisor), 2006,
Resident Clinical Research Award, American Society of Therapeutic Radiology and Oncology (Faculty Advisor), 2003,
Marquis Who's Who in Medicine, 2002,
Philadelphia Magazine, Best Docs, Radiation Oncology, 2002,
Select Recent Publications:
Rash, DL, Lee, YC, Kashefi, A, Durbin-Johnson, B, Mathai, M, Valicenti, R, Mayadev, JS. Clinical response of pelvic and para-aortic lymphadenopathy to a radiation boost in the definitive management of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys., 87(2): 317-22. 2013
Lim, J, Durbin-Johnson, B, Valicenti, R, Mathai, M, Stern, RL, Mayadev, J, ,. The impact of maximum rectal distention and tandem angle on rectal dose delivered in 3D planned gynecologic high dose-rate brachytherapy. Int. J. Gynecol. Cancer, 23(6): 1078-83. 2013
Rash, D, Hagar, Y, Cui, J, Hunt, JP, Valicenti, R, Mayadev, J, ,. Interfraction motion of the vaginal apex during postoperative intensity modulated radiation therapy: are we missing the target? Int. J. Gynecol. Cancer, 23(2): 385-92. 2013
Kunos, CA, Winter, K, Dicker, AP, Small, W, Abdul-Karim, FW, Dawson, D, Jhingran, A, Valicenti, R, Weidhaas, JB, Gaffney, DK. Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis. Int. J. Gynecol. Cancer, 23(4): 615-21. 2013
Lim, J, Durbin-Johnson, B, Valicenti, R, Mathai, M, Stern, RL, Mayadev, J. The impact of body mass index on rectal dose in locally advanced cervical cancer treated with high-dose-rate brachytherapy. Brachytherapy, 12(6): 550-4. 2013
Valicenti, RK, Thompson, I, Albertsen, P, Davis, BJ, Goldenberg, SL, Wolf, JS, Sartor, O, Klein, E, Hahn, C, Michalski, J, Roach, M, Faraday, MM, ,. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. (ASTRO/AUA Joint Approved Publication). Int J Radiat Oncol Biol Phys., 86(5): 822-8. 2013
Thompson, IM, Valicenti, RK, Albertsen, P, Davis, BJ, Goldenberg, SL, Hahn, C, Klein, E, Michalski, J, Roach, M, Sartor, O, Wolf, JS, Faraday, MM. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. (ASTRO/AUA Joint Approved Publication). The Journal of Urology, 190(2): 441-9. 2013
Greene, DE, Mayadev, JS, Valicenti, RK. Radiation treatment for patients with intermediate-risk prostate cancer. Therapeutic Advances in Urology, 4(3): 113-24. 2012
Michalski, J, Winter, K, Roach, M, Markoe, A, Sandler, HM, Ryu, J, Parliament, M, Purdy, JA, Valicenti, RK, Cox, JD. Clinical Outcome of Patients Treated With 3D Conformal Radiation Therapy (3D-CRT) for Prostate Cancer on RTOG 9406. Int J Radiat Oncol Biol Phys., 83(3): e363-70. 2012
Perks JR, Stanic S, Stern RL, Henk B, Nelson MS, Harse RD, Mathai M, Purdy JA, Valicenti RK, Siefkin AD, Chen AM. Failure Mode and Effect Analysis for Delivery of Lung Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2011 Dec 22. [Epub ahead of print]
Stanic S, Mathai M, Cui J, Purdy JA, Valicenti RK. Relationship Between Pelvic Organ-at-Risk Dose and Clinical Target Volume in Postprostatectomy Patients Receiving Intensity-Modulated Radiotherapy. Int J Radiat Oncol Biol Phys. 2011 Apr 30. [Epub ahead of print]
Valicenti RK, Bae K, Michalski J, Sandler H, Shipley W, Lin A, Cox J. Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06. Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1323-9.
Valicenti RK, Trabulsi E, Intenzo C, Lavarino J, Xu Y, Chervoneva I. A Phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first report of a completed study. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):732-7. Epub 2010 Apr 14.